Learning from FAME: the need for sham controls in trials of stable coronary disease

Affiliations

¹ Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; Atlanta VA Medical Center, Atlanta, Georgia. Electronic address: njr@emory.edu.
² Department of Bioethics, National Institutes of Health Clinical Center, Bethesda, Maryland.

Free article

Editorial

Spencer B King 3rd et al. JACC Cardiovasc Interv. 2014 Mar.

Free article

. 2014 Mar;7(3):342-4.

doi: 10.1016/j.jcin.2014.02.001.

¹ Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; Atlanta VA Medical Center, Atlanta, Georgia. Electronic address: njr@emory.edu.
² Department of Bioethics, National Institutes of Health Clinical Center, Bethesda, Maryland.

No abstract available

Comment on

Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. De Bruyne B, et al. N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27. N Engl J Med. 2012. PMID: 22924638 Clinical Trial.